HCV protease inhibitors bring new options for patients.
作者信息
Traynor Kate
出版信息
Am J Health Syst Pharm. 2011 Aug 1;68(15):1372, 1374, 1379. doi: 10.2146/news110051.
PMID:21785015
Abstract
摘要
相似文献
1
HCV protease inhibitors bring new options for patients.丙型肝炎病毒蛋白酶抑制剂为患者带来了新的选择。
Am J Health Syst Pharm. 2011 Aug 1;68(15):1372, 1374, 1379. doi: 10.2146/news110051.
2
Resistance to anti-HCV protease inhibitors.对 HCV 蛋白酶抑制剂的耐药性。
Curr Opin Virol. 2011 Dec;1(6):599-606. doi: 10.1016/j.coviro.2011.10.001. Epub 2011 Oct 28.
3
[New times for the treatment of chronic hepatitis C].[慢性丙型肝炎治疗的新时代]
Ugeskr Laeger. 2012 Mar 19;174(12):795.
4
[Therapy of hepatitis C: new inhibitors as hammers against HCV].[丙型肝炎的治疗：新型抑制剂作为对抗丙肝病毒的“锤子”]
MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:10-1.
5
New developments in HCV therapy.HCV 治疗的新进展。
J Viral Hepat. 2012 Jan;19 Suppl 1:48-51. doi: 10.1111/j.1365-2893.2011.01526.x.
6
Infectious diseases. First specific drugs raise hopes for hepatitis C.传染病。首批特效药物为丙型肝炎带来希望。
Science. 2011 Apr 8;332(6026):159-60. doi: 10.1126/science.332.6026.159.
7
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.血浆载脂蛋白 H 限制 HCV 复制，并与基于 NS3 蛋白酶抑制剂的治疗应答相关。
Liver Int. 2015 Jul;35(7):1833-44. doi: 10.1111/liv.12759. Epub 2015 Jan 23.
8
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.利巴韦林对α干扰素与蛋白酶抑制剂博赛匹韦或特拉匹韦联合治疗期间丙型肝炎病毒复制子RNA下降的影响
Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.
9
[A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].丙型肝炎治疗的新时代：“现在治疗可以个体化了”（医学博士德克·艾内克访谈）
MMW Fortschr Med. 2011 Jul 21;153(29-31):17.
10
Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.博赛匹韦的研发：慢性丙型肝炎感染的首个直接抗病毒治疗药物。
Ann N Y Acad Sci. 2013 Jul;1291:69-76. doi: 10.1111/nyas.12218.
Zotero 插件